Compare IZEA & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | IPSC |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.8M | 58.3M |
| IPO Year | N/A | 2021 |
| Metric | IZEA | IPSC |
|---|---|---|
| Price | $4.41 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 58.7K | ★ 1.5M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $36,176,492.00 | ★ $113,337,000.00 |
| Revenue This Year | N/A | $1,590.09 |
| Revenue Next Year | $15.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.12 | ★ 4122.69 |
| 52 Week Low | $1.68 | $0.34 |
| 52 Week High | $5.86 | $1.19 |
| Indicator | IZEA | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 61.52 |
| Support Level | $4.30 | $0.91 |
| Resistance Level | $4.74 | $1.05 |
| Average True Range (ATR) | 0.17 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.67 | 66.72 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.